Sage Therapeutics, Inc. (NASDAQ:SAGE) Given Average Rating of “Hold” by Brokerages

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have received an average rating of “Hold” from the twenty analysts that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, sixteen have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $10.53.

SAGE has been the topic of several research analyst reports. Piper Sandler lowered their target price on shares of Sage Therapeutics from $26.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Royal Bank of Canada upgraded shares of Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 target price on the stock in a report on Thursday, November 21st. Oppenheimer cut their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Wednesday, October 30th. Truist Financial lowered their price target on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating on the stock in a report on Wednesday, October 30th. Finally, TD Cowen cut their price objective on Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating for the company in a report on Thursday, November 21st.

Institutional Trading of Sage Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Headlands Technologies LLC increased its stake in Sage Therapeutics by 245.3% in the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 2,782 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Sage Therapeutics by 66.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock worth $85,000 after acquiring an additional 4,672 shares during the period. Creative Planning purchased a new stake in shares of Sage Therapeutics during the third quarter worth about $88,000. Quest Partners LLC raised its stake in Sage Therapeutics by 14.5% during the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 1,486 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Sage Therapeutics in the 3rd quarter worth approximately $146,000. 99.22% of the stock is currently owned by institutional investors.

Sage Therapeutics Stock Down 5.1 %

Shares of SAGE opened at $5.55 on Friday. The company has a market capitalization of $339.51 million, a P/E ratio of -0.99 and a beta of 0.91. Sage Therapeutics has a twelve month low of $4.62 and a twelve month high of $28.26. The firm has a 50 day moving average of $5.57 and a 200 day moving average of $7.62.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The business had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. During the same period in the previous year, the business posted ($2.81) EPS. The firm’s revenue for the quarter was up 337.1% on a year-over-year basis. On average, sell-side analysts expect that Sage Therapeutics will post -6.53 EPS for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.